Corrigendum.
Following publication of the Research Article by Orazio Caffo, Giovanni Lo Re, Teodoro Sava, Sebastiano Buti, Cosimo Sacco, Umberto Basso, Fable Zustovich, Michele Lodde, Alessandra Perin, Gaetano Facchini, Antonello Veccia, Francesca Maines, Carmen Barile, Lucia Fratino, Angela Gernone, Rocco De Vivo, Giovanni L Pappagallo & Enzo Galligioni titled ‘Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients’, which appeared in the January 2015 issue of Future Oncology (11[6], 965–973 [2015]; www.futuremedicine.com/doi/full/10.2217/fon.14.284), it has come to our attention that the affiliation number 6 was incorrectly presented as: Medical Oncology Department, Istituto Oncologico Veneto, Padova, Italy. This should have been presented as: Medical Oncology Unit 1; Department of Clinical & Experimental Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova Italy. The authors and editors of Future Oncology would like to sincerely apologize for any inconvenience or confusion this may have caused.